Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec042018	Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting FT500, First-ever iPSC-derived Cell Product Candidate Cleared for U.S. Clinical Investigation by FDA, Featured in Oral Presentation SAN DIEGO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of Read All »	View HTML
Toggle SummaryDec032018	Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Humanized Antibody Fragments and Antigen-Binding Domains Targeting BCMA SAN DIEGO , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company Read All »	View HTML
Toggle SummaryNov302018	Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy Company to Initiate First-ever U.S. Clinical Investigation of iPSC-derived Cell Product FT500 to be Featured in Oral Presentation on Monday, December 3 at ASH Annual Meeting SAN DIEGO , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical Read All »	View HTML
Toggle SummaryNov112018	Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500 NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies and Solid Tumors Disease Control Shown in All Subjects Re-treated with Second Dose of NK100 No NK100-related Dose Limiting Toxicities Reported Submitted Data to FDA Demonstrating FT500 Master iPSC Bank is Free of Read All »	View HTML
Toggle SummaryNov082018	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML
Toggle SummaryNov012018	Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress Twenty Subjects Treated across Three Phase 1 Studies of FATE-NK100 Entered into Off-the-Shelf, iPSC-derived CAR-T Cell Collaboration with ONO Pharmaceutical Completed $144M Common Stock Public Offering Three Oral and Four Poster Presentations Covering Product Pipeline will be Presented at ASH Read All »	View HTML
Toggle SummaryNov012018	Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting Three Oral and Four Poster Presentations Covering Product Pipeline Accepted for Presentation Company to Host Investor Event at ASH on November 30 SAN DIEGO , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the Read All »	View HTML
Toggle SummaryOct292018	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results SAN DIEGO , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast Read All »	View HTML
Toggle SummaryOct042018	Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations SAN DIEGO , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Wen Bo Wang , Ph.D., a leading expert in the manufacture of Read All »	View HTML
Toggle SummarySep252018	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.